Copanlisib
Germinal Center B-cell Type (GCB)
National Cancer Institute (NCI)Small moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
23 Active assets in the Germinal Center B-cell Type (GCB) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Inno-206 Li Zhiming | Phase 2/3 | BB |
PREDNISONE TABLETS National Cancer Institute (NCI) | Phase 2/3 | BB |
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER Mayo Clinic | Phase 2/3 | BB |
Cyclophosphamide Li Zhiming | Phase 2/3 | BB |
VINCRISTINE SULFATE National Cancer Institute (NCI) | Phase 2/3 | BB |
View all 24 →
Same molecule, other indications
Copanlisib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →